REG - Cizzle Biotechnology - Total Voting Rights

Cizzle Biotechnology HoldingsAnnouncement

30/04/2024 17:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240430:nRSd5879Ma&default-theme=true

RNS Number : 5879M  Cizzle Biotechnology Holdings PLC  30 April 2024

30 April 2024

 

Cizzle Biotechnology Holdings Plc

 

("Cizzle Biotechnology" or the "Company")

 

Total Voting Rights

 

Cizzle Biotechnology Holdings PLC (LSE: CIZ), the UK based diagnostics
developer, makes the following announcement in accordance with Rule 5.6.1 of
the Financial Conduct Authority's ("FCA") Disclosure Guidance and Transparency
Rules.

 

As of 30 April 2024, the Company's issued ordinary share capital consists of
396,391,773 ordinary shares of 0.01 pence each, each with one voting right.
 The Company holds no ordinary shares in Treasury.  Therefore, the Company's
total number of ordinary shares and voting rights is 396,391,773 and this
figure may be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 George Payne

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

 

Cizzle Biotechnology is developing a blood test to facilitate the early
detection of lung cancer based on the ability to detect a stable plasma
biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally occurring
cell nuclear protein involved in DNA replication, and the targeted CIZ1B
variant has been shown to be highly correlated with early-stage lung cancer.
The Company's proprietary technology results from the work of Professor
Coverley and colleagues at the University of York.

 

For more information please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

 

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAPLEDSELEEA